Epigenetic silencing, mutations and defective glycolysation of death receptors occurs frequently in TRAIL-resistant models; we initialised the study through profiling the target protein expression of AZD5582 and TRAIL and detected no statistically significant differences between sensitive and resistant cell lines in the breast tumour cell panel. Here, TNFSF10 is linked to breast neoplasm.